MOLN - Molecular Partners AG
| Previous close | 6.67 |
| Open | 6.65 |
| Bid | 2.69 x 900 |
| Ask | 10.73 x 1800 |
| Day's range | 6.65 - 6.75 |
| 52-week range | 5.50 - 8.00 |
| Volume | |
| Avg. volume | 1,666 |
| Market cap | 239.778M |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.73 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.60 |
Simply Wall St.Companies Like Molecular Partners (VTX:MOLN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Simply Wall St.
Getting In Cheap On Molecular Partners AG (VTX:MOLN) Is Unlikely
Molecular Partners AG's ( VTX:MOLN ) price-to-sales (or "P/S") ratio of 10.1x might make it look like a sell right now...
- Simply Wall St.
Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 79% over the last five years
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
- Simply Wall St.
Molecular Partners Full Year 2022 Earnings: Beats Expectations
Molecular Partners ( VTX:MOLN ) Full Year 2022 Results Key Financial Results Revenue: CHF189.6m (up by CHF179.8m from...
- Simply Wall St.
Hedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the company
A look at the shareholders of Molecular Partners AG ( VTX:MOLN ) can tell us which group is most powerful. With 41...
- Simply Wall St.
Molecular Partners AG's (VTX:MOLN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Molecular Partners (VTX:MOLN) has had a great run on the share market with its stock up by a significant 20% over the...
- Simply Wall St.
Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 77% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...